SITC 27th Annual Meeting Presentations
October 26-28, 2012
Bethesda North Marriott Hotel & Conference Center
North Bethesda, MD
Presentations are posted online based upon presenter approval.
Program Schedule
Friday, October 26 |
||
| 7:50 am - 8:00 am | President's Welcome Thomas F. Gajewski, MD, PhD - University of Chicago |
|
| 8:00 am - 8:45 am | Richard V. Smalley, MD Memorial Lectureship  Theresa L. Whiteside, PhD - University of Pittsburgh Cancer Institute |
|
| Plenary Session 301: T Cell Modulating Strategies Co-chairs: Nicholas P. Restifo, MD - National Cancer Institute Cassian Yee, MD - Fred Hutchinson Cancer Research Center |
||
| 8:45 am - 9:15 am | Curative Cancer Immunotherapy Using Stem Cell-like T Cells Nicholas P. Restifo, MD - National Cancer Institute |
|
| 9:15 am - 9:45 am | Adoptive T Cell Therapy: Faster, Higher, Stronger Cassian Yee, MD - Fred Hutchinson Cancer Research Center |
|
| 10:15 am - 10:45 am | Profound Negative Regulation of T Cell Immunity by Nk Cells Pamela S. Ohashi, PhD - Ontario Cancer Institute/University Health Network |
|
| 10:45 am - 11:00am | Memory CD8+ T Cells Induce Precocious Effector Differentiation of Naïve CD8+ T Cells in a Fasl-Fas Dependent Manner: a New Mode of T-T Lymphocyte Interaction and Cross Talk Christopher A. Klebanoff, MD - National Institutes of Health |
|
| 11:00 am - 11:15 am | Optimizing the Therapeutic Potential of PD-L1 Blockade as a Single Agent and Through Combination Therapy Bryan A. Irving, PhD - Genentech, Inc. |
|
| 11:15 am - 11:30 am | Blockade of PD-L1 Mediated Immunosupression for Cancer Therapy - MEDI4736, Monoclonal Antibody Discovery and Preclinical Development Ross A. Stewart, PhD - MedImmune |
|
| Plenary Session 302: Late-Breaking Oral Abstracts | ||
| 11:30 am - 11:45 am | A Phase II Study with the Anti-CTLA-4 mAb Tremelimumab in Advanced Malignant Mesothelioma: MESOTTREM-2008 Luana Calabró, MD - University Hospital of Siena |
|
| 11:45 am - 12:00 pm | Treatment of Non-Hodgkin Lymphoma with CAR-Transduced CD19-Specific Central Memory Derived T Cells Stephen J. Forman, MD - City of Hope |
|
| 12:00 pm - 1:30 pm | Poster Viewing and Presentations | |
| Concurrent Session 304: DC Subsets / Cancer Vaccines Co-chairs: Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute Cornelis J.M. Melief, MD, PhD - Leiden University Medical Center |
||
| 1:30 pm - 1:55 pm | Promoting the Effectiveness of Synthetic Cancer Vaccines Cornelis J.M. Melief, MD, PhD - Leiden University Medical Center |
|
| 1:55 pm - 2:08 pm | Preoperative Sipuleucel-T Results in Tumor Lymphocyte Infiltration in Prostate Cancer Specimens: Evidence of Immune Activation and Response Within the Prostate Tumor Microenvironment Lawrence Fong, MD - University of California, San Francisco |
|
| 2:08 pm - 2:21 pm | A Novel Dendritic Cell-based Vaccine for Her-2-Positive Early Breast Cancer Brian Czerniecki, MD, PhD - University of Pennsylvania |
|
| 2:21 pm - 2:34 pm | Randomized Trial of Two Active-Specific Immunotherapy Products Derived From Autologous, Proliferating, Self-renewing Tumor Cells in Patients with Metastatic Melanoma Robert O. Dillman, MD, FACP - Hoag Cancer Center |
|
| 2:34 pm - 3:00 pm | Optimization of DC-based Cancer Therapies Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute |
|
| 1:30 pm - 3:00 pm | Concurrent Session 305: Targeting Immune Suppression Co-chairs: Michael H. Kershaw, PhD - Peter MacCallum Cancer Centre David H. Munn, MD - Georgia Health Sciences University |
|
| 1:30 pm - 2:00 pm | IDO and Immune Suppression David H. Munn, MD - Georgia Health Sciences University |
|
| 2:00 pm - 2:15 pm | Enrichment of CTLA4+CD39+CD25+FOXP3+ Regulatory T Cells in Head and Neck Cancer Patients is Promoted by Therapy with Cetuximab and Correlated with Clinical Outcome Hyun-Bae Jie, PhD - University of Pittsburgh |
|
| 2:15 pm - 2:30 pm | mir-124 as a Novel Immunotherapeutic Molecule to Reverse Gliomamediated Immune Suppression and Enhance Anti-Tumor Clearance Amy B. Heimberger, MD - University of Texas MD Anderson Cancer Center |
|
| 2:30 pm - 3:00 pm | The Tumor Microenvironment Can Vary with Anatomical Site to Affect Responses to Therapy Michael H. Kershaw, PhD - Peter MacCallum Cancer Centre |
|
| Plenary Session 306: Immunity of Oncolytic Viruses Co-chairs: Howard L. Kaufman, MD, FACS - Rush University Medical Center Aladar A. Szalay, PhD - Genelux Corporation |
||
| 3:15 pm - 3:45 pm | Tropism of Oncolytic Vaccinia Virus Constructs for Human Mononuclear Cell Subsets Boris Minev, MD - Genelux Corporation |
|
| 3:45 pm - 4:15 pm | Oncolytic Virotherapy as Cancer Immunotherapy Richard Vile, PhD - Mayo Clinic |
|
| 4:15 pm - 4:45 pm | Modulating the Tumor Microenvironment to Enhance Antitumor Immunity in Preclinical and Clinical Settings: Antigen Encoding Poxvirus Vectors Overcome Immune Escape Edmund C. Lattime, PhD - The Cancer Institute of New Jersey |
|
| 4:45 pm - 5:00 pm | Effect of HCV Viraemia on NK Cells Maria Libera Ascierto, PhD - National Institutes of Health |
|
| 5:00 pm - 5:15 pm | Combination Therapy of Intratumoral CRT/E7 Vaccinia Virus and Cisplatin Treatment Enhance the Antigen-Specific T Cell Immune Responses and Therapeutic Antitumor Effects Sung Yong Lee, MD, PhD - Johns Hopkins Medical Institutions |
|
| 5:15 pm - 5:30 pm | Cancer Immunotherapy Guidelines (CIG) Update Howard L. Kaufman, MD, FACS - Rush University Medical Center |
|
| 5:30 pm - 5:45 pm | US Food and Drug Administration (FDA) Update Raj K. Puri, MD, PhD - US Food and Drug Administration, CBER |
|
| 5:45 pm - 6:00 pm | National Cancer Institute (NCI) Update William Merritt, PhD - National Cancer Institute |
|
| 6:00 pm - 6:30 pm | SITC Membership Business Meeting | |
| 6:30 pm - 8:00 pm | Poster and Networking Reception | |
| 8:00 pm - 10:00 pm | Early Career Scientists Evening Networking Event | |
|
||
| 7:00 am - 7:45 am | Early Career Scientists "Meet-the-Expert" Breakfast | |
| 8:00 am - 8:45 am | Keynote Address: Using Genomics To Understand Cancer Immunoediting And Guide Immunotherapy Robert D. Schreiber, PhD - Washington University St. Louis |
|
| Plenary Session 401: Combining Immunotherapy and Other Therapies Co-chairs: Antoni Ribas, MD - UCLA Medical Center Laurence Zitvogel, MD, PhD - Institute Gustave Roussy |
||
| 8:45 am - 9:15 am | Combining Immunotherapy and Targeted Therapy for Melanoma Antoni Ribas, MD - UCLA Medical Center |
|
| 9:15 am - 9:30 am | PD-1/PD-L1 Blockade after Transient Lymphodepletion to Treat Myeloma Bryon D. Johnson, PhD - Medical College of Wisconsin |
|
| 9:30 am - 9:45 am | Pharmacokinetics and Immunological Effects of Human Il-15/Il-15Ra Heterodimeric Complexes in Mice and Macaques Cristina Bergamaschi, PhD - Frederick National Laboratory for Cancer Research |
|
| 9:45 am - 10:00 am | ADXS11-001 Lm-LLO Immunotherapy Targeting HPV-E7: Preliminary Safety and Survival Data From A Phase 2 Study in Indian Women With Recurrent/Refractory Cervical Cancer Robert Petit, PhD - Advaxis |
|
| 10:30 am - 11:00 am | Immunomodulation and Tyrosine Kinase Inhibition Ronald DeMatteo, MD, FACS - Memorial Sloan-Kettering Cancer Center |
|
| 11:00 am - 11:30 am | Imatinib Mesylate: An Efficient Cancer Immunotherapy Laurence Zitvogel, MD, PhD - Institute Gustave Roussy |
|
| Plenary Session 402: Critical Issues in Immunotherapy Clinical Trials Co-chairs: Samir N. Khleif, MD - Georgia Health Sciences Howard Streicher, MD - National Institutes of Health |
||
| 11:30 am - 11:45 am | The Projection of Immunotherapy Clinical Design of the 21st Century Howard Streicher, MD - National Institutes of Health |
|
| 11:45 am - 12:00 pm | Critical Issues for Early Trial Design in Immunotherapy Osama Rahma, MD - National Cancer Institute |
|
| 12:00 pm - 12:15 pm | Design Issues in the Immunotherapy Combinatorial Trials Antoni Ribas, MD - UCLA Medical Center |
|
| Plenary Session 403: Late-Breaking Oral Abstract Chair: Francesco Marincola, MD - National Institutes of Health |
||
| 12:30 pm - 12:45 pm | 12-Chemokine Gene Signature Identifies Lymph Node-Like Structures In Melanoma: Potential For Patient Selection For Immunotherapy? Jim Mulè, PhD - H. Lee Moffitt Cancer Center & Research Institute |
|
| 12:45 pm - 2:00 pm | Poster Viewing and Presentations | |
| Concurrent Session 404: T Cell Manufacture and Potency Testing Co-chairs: Daniel J. Powell, Jr., PhD - University of Pennsylvania David F. Stroncek, MD - National Institutes of Health |
||
| 2:00 pm - 2:30 pm | TIL Adoptive Cell Therapy for Melanoma: Trials and Tribulations in the Quest for FDA Approval Laszlo G. Radvanyi, PhD - MD Anderson Cancer Center |
|
| 2:30 pm - 3:00 pm | Developing Commercially Relevant T Cell Therapy Manufacturing Processes Robert Keefe, PhD - Lonza Walkersville, Inc. |
|
| 3:00 pm - 3:30 pm | Artificial Antigen Presenting Cells as a Standardized Platform for TIL Expansion Daniel J. Powell, Jr., PhD - University of Pennsylvania |
|
| Concurrent Session 405: Single Cell High Throughput Technologies Immune Monitoring Co-chairs: Alessandra Cesano, MD, PhD - Nodality Begonya Comin-Anduix, PhD - UCLA School of Medicine |
||
| 2:00 pm - 2:30 pm | A Single Cell Network Profiling (SCNP) View of the Immune System Alessandra Cesano, MD, PhD - Nodality, Inc. |
|
| 2:30 pm - 2:45 pm | Dissection of Anti-CTLA4-induced Cytotoxic T Cell Responses in Melanoma Pia Kvistborg, MD - Netherlands Cancer Institute |
|
| 2:45 pm - 3:00 pm | High-Throughput Identification of Biomarkers of Longevity in Ipilimumab-Treated Melanoma Patients Using Polychromatic Flow Cytometry Janet C. Siebert, MS - CytoAnalytics |
|
| 3:00 pm - 3:30 pm | A Shape for Cancer and Immunity at the Single Cell Level Garry P. Nolan, PhD - Stanford School of Medicine |
|
| 4:00 pm - 5:20 pm | Plenary Session 406: Presidential Abstract Session Chair: Thomas F. Gajewski, MD, PhD - University of Chicago |
|
| 4:00 pm - 4:20 pm | Forcing NF-sB in T Cells Promotes Tumor Rejection Cesar Evaristo, PhD - University of Chicago |
|
| 4:20 pm - 4:40 pm | CARs For Childhood Cancer: Development and Comparison of Permanently and Transiently-Modified T-cells Targeting All and Neuroblastoma Nathan Singh - University of Pennsylvania |
|
| 4:40 pm - 5:00 pm | Inhibition of Glycolytic Flux Enhances CD8+ T Cell Memory, Stemness and Anti-Tumor Function Madhusudhanan Sukumar, PhD - National Cancer Institute |
|
| 5:00 pm - 5:20 pm | Tgfß is a Master Regulator of the Pro-immunogenic Effects of Radiotherapy Claire Vanpouille-Box, PhD - NYU School of Medicine |
|
| Cancer Immunotherapy Trials Network (CITN) Update | ||
| 5:20 pm - 5:30 pm | Martin A. “Mac” Cheever, MD - CITN Principal Investigator, Fred Hutchinson Cancer Research Center | |
| 5:30 pm - 5:35 pm | IL15 Trial Jeffrey S. Miller, MD - University of Minnesota Cancer Center |
|
| 5:35 pm - 5:40 pm | IL7 Trial Lawrence Fong, MD - University of California, San Francisco |
|
| 5:40 pm - 5:45 pm | IDO Inhibitor Trial (Melanoma) Craig L. Slingluff, Jr., MD - University of Virginia |
|
| 5:45 pm - 5:50 pm | IDO Inhibitor Trial (Ovarian Cancer) Kunle Odunsi, MD, PhD - Roswell Park Cancer Institute |
|
| 5:50 pm - 6:15 pm | Awards Ceremony | |
| 6:15 pm - 8:00 pm | Presidential Reception with Poster Viewing | |
| 8:00 pm | The Checkpoints Performance | |
|
||
| Plenary Session 500: Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS) Co-chairs: Philip D. Greenberg, MD - University of Washington Steven A. Rosenberg, MD, PhD - National Cancer Institute |
||
| 8:00 am - 8:30 am | Adoptive Immunotherapy of Cancer Steven A. Rosenberg, MD, PhD - National Cancer Institute |
|
| 8:30 am - 9:00 am | Building a Better T Cell for Targeting Tumors Philip D. Greenberg, MD - University of Washington |
|
| 9:00 am - 9:30 am | Targeting CD19 in Adult and Pediatric Leukemia Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center |
|
| 9:30 am - 9:45 am | Adoptive T Cell Therapy with a TCR Engineered for Nanomolar Affinity Shows Improved Anti-Tumor Efficacy Compared to the Micromolar Wildtype TCR Carolina M. Soto - University of Illinois |
|
| 9:45 am - 10:00 am | Selection of PD-1, LAG-3, TIM-3 and 41BB positive CD8 T Cells in the Fresh Tumor Digest Enriches for Melanoma-Reactive Cells Alena Gros, PhD - National Cancer Institute |
|
| 10:00 am - 10:15 am | Role of the PD-1/PD-L1 Pathway on Regulatory T Cell Development, Induction and Iunction in Vivo Justin P. Kline, MD - University of Chicago |
|
| 10:15 am | Annual Meeting Adjourns | |
| 10:30 am - 12:00 pm | Hot Topic Symposium | |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
- Go to SITC’s YouTube channel to hear Annual Meeting Organizers talk about highlights of the meeting!
- October 24, 2012
SITC Early Career Scientists Professional Development Session - October 24-25, 2012
SITC Workshop – Focus on the Target: The Tumor Microenvironment - October 25, 2012
SITC Primer on Tumor Immunology and Cancer Immunotherapy™ - October 26-28, 2012
SITC 27th Annual Meeting - October 28, 2012
SITC Hot Topic Symposium: PD-1/PD-L1: Right on Target
SITC has opportunities and solutions available no matter what your goal!
SITC offers General, Marketing and Educational support opportunities for the Society as well as for all SITC educational programs.
Platinum
Silver
EMD Serono
Prometheus
Bronze
Amgen
Celgene
Dendreon
Otsuka
